US-CONGRESS HR5880: Fight Illicit Pill Presses Act
HR5880, the Fight Illicit Pill Presses Act, has been forwarded to the full committee. This bill aims to combat illicit pill presses by enhancing DEA and FDA enforcement, potentially increasing compliance burdens for pharmaceutical manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) should confirm how it applies to their specific situation before acting. There is a time constraint attached: Unknown; bill passage expected within months. Prepare now.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The bill advances to full committee, signaling likely passage. It will impose stricter controls on pill press equipment and related substances, requiring enhanced recordkeeping and reporting.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)
What you must do
Monitor legislative progress and prepare for potential new compliance requirements regarding equipment tracking and controlled substance reporting.
Deadline
Unknown; bill passage expected within months. Prepare now.
Source: https://www.congress.gov/bill/119th-congress/house-bill/5880
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trial